Trial of Pembrolizumab and Radiotherapy in Melanoma
Status:
Terminated
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Around 13,000 participants are diagnosed with melanoma in the UK each year and that number is
growing quicker than any other cancer. About 20% of participants will see their cancer return
following their initial treatment and at present would survive a median time of 912 months.
In recent years, the development of new effective drugs has revolutionised the treatment of
advanced melanoma, However, response rates are still low and new therapeutic approaches are
needed.
This is a phase II study to look at the effectiveness and safety of the combination of a new
drug called pembrolizumab plus radiotherapy compared to pembrolizumab alone. The purpose of
this study is to see if the addition of radiotherapy to pembrolizumab is better than
pembrolizumab alone by measuring how long these treatments can control the growth of the
cancer. Also it will assess if by adding radiotherapy the investigators can see its effects
not only in the tumour that has had radiotherapy but also in other tumours in the rest of the
body.